Based on the analysis of Phenixfin's profitability, liquidity, and operating efficiency, Phenixfin is doing better financially today then in previous quarter. It has a moderate chance of reporting better financial numbers in February. At this time, Phenixfin's Accounts Payable is fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 362.4 M in 2026, whereas Short and Long Term Debt Total is likely to drop slightly above 128.6 M in 2026. Key indicators impacting Phenixfin's financial strength include:
The essential information of the day-to-day investment outlook for Phenixfin includes many different criteria found on its balance sheet. An individual investor should monitor Phenixfin's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Phenixfin.
Please note, the imprecision that can be found in Phenixfin's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Phenixfin. Check Phenixfin's Beneish M Score to see the likelihood of Phenixfin's management manipulating its earnings.
Phenixfin Stock Summary
Phenixfin competes with OFS Capital, Great Elm, Hennessy, Bluemount Holdings, and Auburn National. The firm seeks to invest in privately negotiated debt and equity securities of small and middle market companies. PhenixFIN Corporation was founded in 2010 and is headquartered in New York, New York. Phenixfin Corp operates under Asset Management classification in the United States and is traded on NASDAQ Exchange. It employs 7 people.
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
Cash flow analysis captures how much money flows into and out of Phenixfin. It measures of how well Phenixfin is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Phenixfin brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Phenixfin had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Phenixfin has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
Comparative valuation techniques use various fundamental indicators to help in determining Phenixfin's current stock value. Our valuation model uses many indicators to compare Phenixfin value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Phenixfin competition to find correlations between indicators driving Phenixfin's intrinsic value. More Info.
Phenixfin is regarded fourth in return on equity category among its peers. It is considered to be number one stock in return on asset category among its peers reporting about 1.20 of Return On Asset per Return On Equity. At this time, Phenixfin's Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Phenixfin's earnings, one of the primary drivers of an investment's value.
Phenixfin Systematic Risk
Phenixfin's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Phenixfin volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was three with a total number of output elements of fifty-eight. The Beta measures systematic risk based on how returns on Phenixfin correlated with the market. If Beta is less than 0 Phenixfin generally moves in the opposite direction as compared to the market. If Phenixfin Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Phenixfin is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Phenixfin is generally in the same direction as the market. If Beta > 1 Phenixfin moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Phenixfin Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Phenixfin's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Phenixfin growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of Phenixfin help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Phenixfin. We use our internally-developed statistical techniques to arrive at the intrinsic value of Phenixfin based on widely used predictive technical indicators. In general, we focus on analyzing Phenixfin Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Phenixfin's daily price indicators and compare them against related drivers.
When running Phenixfin's price analysis, check to measure Phenixfin's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Phenixfin is operating at the current time. Most of Phenixfin's value examination focuses on studying past and present price action to predict the probability of Phenixfin's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Phenixfin's price. Additionally, you may evaluate how the addition of Phenixfin to your portfolios can decrease your overall portfolio volatility.